The primary outcome was the diagnostic performance of serum IFITM1/2/3 levels in distinguishing CAD and AMI patients from healthy controls, as assessed by receiver operating characteristic (ROC) analysis. This evidence concerns the gene IFITM1 and coronary artery disorder.